Clinical trials: Lung Cancer Patient
Extensive Stage Lung Small Cell Carcinoma, Extrapulmonary Small Cell Neuroendocrine Carcinoma
Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs
This phase II trial studies how well berzosertib (M6620) works when given in combination with topotecan hydrochloride (topotecan) compared with topotecan alone in treating patients with small cell lung cancer that has come back…
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Extrapulmonary Small Cell Neuroendocrine Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma
- Trial name
- NCT03896503
- Testing
- Berzosertib, Biopsy Procedure, Biospecimen Collection
- Where
- 33 sites in United States
- Volunteers
- 104 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Small Cell, Small Cell Lung Cancer
Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer
The purpose of this study is to evaluate the objective tumor response rate to SNS-595 in patients with small cell lung cancer (SCLC).
- Trial name
- NCT00298896
- Testing
- SNS-595
- Where
- 17 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- Sunesis Pharmaceuticals
Colorectal Cancer, Metastatic Cancer
Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer
RATIONALE: Vaccines made from a gene-modified virus and a person's white blood cells may make the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00103142
- Testing
- falimarev, inalimarev, sargramostim
- Where
- 6 sites in United States
- Volunteers
- 74 people
- Sponsor
- Michael Morse, MD
Carcinoma, Non-Small-Cell Lung
Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC
This will be the first prospective study where patients will be selected on the basis of two measures of the epidermal growth factor receptor (EGFR) pathway.
- Trial name
- NCT00294762
- Testing
- Tarceva, carboplatin, paclitaxel
- Where
- 43 sites in United States, United Kingdom
- Volunteers
- 143 people
- Sponsor
- OSI Pharmaceuticals
Carcinoma, Non-small Cell
Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung
This study will explore the safety and efficacy of the oral PanHER inhibitor PF-00299804 in patients with adenocarcinoma of the lung who are either non-smokers (<100 cigarette, cigar or pipe lifetime) or former light smokers …
- Trial name
- NCT00818441
- Testing
- Dacomitinib (PF-00299804)
- Where
- 41 sites in United States, Hong Kong and 3 more
- Volunteers
- 119 people
- Sponsor
- Pfizer
Recurrent Lung Small Cell Carcinoma
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
This randomized phase II trial studies how well temozolomide with or without veliparib works in treating patients with small cell lung cancer that has returned or does not respond to treatment.
- Trial name
- NCT01638546
- Testing
- Laboratory Biomarker Analysis, Temozolomide, Veliparib
- Where
- 14 sites in United States
- Volunteers
- 97 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
This is a Phase III/IV, single-arm, multicenter study of the long-term safety and efficacy of atezolizumab treatment in participants with Stage IIIb or Stage IV NSCLC who have progressed after standard systemic chemotherapy…
- Trial name
- TAIL (NCT03285763)
- Testing
- Atezolizumab
- Where
- 111 sites in Argentina, Brazil and 22 more
- Volunteers
- 619 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor
Durvalumab Long-Term Safety and Efficacy Study
The aims of the study are to monitor the long-term safety of durvalumab, to provide continued treatment or retreatment with durvalumab to eligible patients, and to collect overall survival (OS) information.
- Trial name
- WAVE (NCT04078152)
- Testing
- Durvalumab
- Where
- 116 sites in United States, Argentina and 29 more
- Volunteers
- 163 people
- Sponsor
- AstraZeneca
Advanced Cancers
Hepatic Impairment Study for Lorlatinib in Cancer Patients
This is a phase 1 study in advanced cancer patients with varied hepatic functions to evaluate the potential effect of hepatic impairment on pharmacokinetics and safety of lorlatinib and provide dose recommendation for patients…
- Trial name
- NCT03726333
- Testing
- lorlatinib
- Where
- 10 sites in United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Metastatic Non Small Cell Lung Cancer
Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations
This is a Phase 4, open label, single arm, multi-center, prospective clinical trial of dacomitinib that will be performed in India.
- Trial name
- NCT04511533
- Testing
- Dacomitinib
- Where
- 15 sites in India
- Volunteers
- 101 people
- Sponsor
- Pfizer
Non-Squamous Non-Small Cell Lung Cancer
An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy
This prospective, multicenter observational study will evaluate the efficacy, safety, and tolerability of Tarceva (erlotinib) as second-line treatment in patients with locally advanced or metastatic non-small cell lung cancer…
- Trial name
- TIME (NCT01664533)
- Testing
- Erlotinib
- Where
- 21 sites in Belgium
- Volunteers
- 57 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients
The primary objective of this open-label, single arm Phase II trial is to explore the efficacy of BIBW 2992 defined by the objective response rate (CR, PR) as determined by the RECIST criteria in patients with EGFR FISH positive…
- Trial name
- NCT00796549
- Testing
- BiBW 2992
- Where
- 13 sites in Italy
- Volunteers
- 70 people
- Sponsor
- Boehringer Ingelheim
Cancer, Thoracic Neoplasms
Improving Cancer On-treatment Symptom Management
Patient-reported outcome measures (PROMs) is an umbrella term that refers to any report on a health status measure that is reported directly by the patient, without the influence of clinicians or anyone else.
- Conditions
- Cancer, Thoracic Neoplasms, Gastrointestinal Cancer, Lung Cancer
- Trial name
- IMPROVE (NCT04589247)
- Where
- 4 sites in United States
- Volunteers
- 104 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Stage IV Non-Small Cell Lung Cancer
Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3
This pilot phase II trial studies how well pemetrexed disodium works in treating patients with stage IV non-small cell lung cancer and an Eastern Cooperative Oncology Group (ECOG) performance status of 3.
- Trial name
- NCT02426658
- Testing
- Laboratory Biomarker Analysis, Pemetrexed Disodium, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
This phase II trial studies how well trametinib and docetaxel work in treating patients with stage IV KRAS mutation positive non-small cell lung cancer or cancer that has come back.
- Conditions
- KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT02642042
- Testing
- Docetaxel, Laboratory Biomarker Analysis, Trametinib
- Where
- 596 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-small Cell Lung
Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer
This study will enroll elderly patients with advanced non-small cell lung cancer who are at high risk of developing chemotherapy toxicity (side effects).
- Trial name
- NCT02590003
- Testing
- Carboplatin, Nab-paclitaxel
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Yale University
Non Small Cell Lung Cancer
Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer
The primary objective for this trial is to determine the biological ability of apricoxib to decrease T reg cells in the peripheral blood and tumor infiltrating lymphocytes in subjects compared to those who have not in subjects…
- Trial name
- NCT01532362
- Testing
- Apricoxib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Carcinoma, Non-Small-Cell Lung
Study to Evaluate Using Nelfinavir With Chemoradiation for Non-small Cell Lung Cancer
This study combines nelfinavir (NFV) with radiation therapy and chemotherapy as a treatment for non-small cell lung cancer (NSCLC) who are considered candidates for pre-operative treatment.
- Trial name
- NCT00791336
- Testing
- Nelfinavir
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Iowa
Cancer
Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients
This research is intended to begin to explore the impact of inspiratory muscle resistance exercise and/or 1,25(OH)2D3 for improving respiratory muscle strength in cancer patients (subjects).
- Trial name
- NCT03469271
- Testing
- 1,25 (OH)2 D3, Inspiratory isometric resistance training, Threshold Inspiratory Muscle Trainer (IMT)
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Mayo Clinic
Non-small Cell Lung Cancer (NSCLC)
PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
PCSK9 mediates immune checkpoint blockade resistance by downregulating tumor cell surface MHC class 1 molecules. This study will evaluate if combining the anti-PCSK9 antibody alirocumab with the anti-PD-1 antibody cemiplimab can…
- Trial name
- NCT05553834
- Testing
- Alirocumab and Cemiplimab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Duke University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.